Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

ABSTRACT: To elucidate the potential role of commensal viruses in the etiology of AR, we performed a metagenomic analysis of nasal lavage fluid (NLF) to identify commensal viruses in the nose of mice colonizing in the specific pathogen-free (SPF) circumstances (Vehicle group). To evaluate the potential role of these commensal viruses, we reduced them in the nose of mice by administrating intranasal drops of broad-spectrum antiviral drug ribavirin daily, starting at 4-week-old and lasting for three weeks (Ribavirin group).

ORGANISM(S): Mus musculus

PROVIDER: GSE271863 | GEO | 2024/08/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:To explore the impact of nasal commensal viruses on the onset and progression of allergic rhinitis, We used single cell RNA sequencing (scRNA-seq) to analyze the diversity of CD45+ cells in the nasal mucosa of mice treated with Vehicle, Ribavirin, Vehicle-OVA, or Ribavirin-OVA.

2024-08-21 | GSE266238 | GEO

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:For analyzing the exploratory nasal commensal viruses, we performed the metatranscriptomic analysis of the nose swabs from the enrolled AR patients both before and after treatments, as well as sequenced the nose swabs from a set of healthy volunteers without AR history.Simultaneously, to assess the expression of interferon-stimulated genes in patients with allergic rhinitis, we analyzed the gene expression of host reads.

2024-08-21 | GSE275114 | GEO

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

| PRJNA1106437 | ENA

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

| PRJNA1149471 | ENA

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

| PRJNA1133765 | ENA

Ribavirin Treated Huh7.5.1 Cells

Project description:The combination of peginterferon and ribavirin is the standard treatment for chronic hepatitis C. Our recent clinical study suggests that ribavirin augments the induction of interferon stimulated genes (ISGs) in patients treated for HCV infection [1]. In order to further characterize the mechanisms of action of ribavirin, we examined the effect of ribavirin treatment on ISG induction in cell culture. In addition, the effect of ribavirin on infectious HCV cell culture systems was also studied. Similar to interferon-alpha, ribavirin potently inhibits JFH-1 infection of Huh7.5.1 cells in a dose-dependent manner, which spans the physiological concentration of ribavirin in vivo. Microarray analysis and subsequent quantitative PCR assays demonstrated that ribavirin treatment resulted in the induction of a distinct set of ISGs. These ISGs, including IRF7 and IRF9 are known to play an important role in anti-HCV responses. When ribavirin is used in conjunction with interferon, induction of specific ISGs is synergistic when compared to either drug applied separately. Direct up-regulation of these antiviral genes by ribavirin is mediated by a novel mechanism different from those associated with interferon signaling and intracellular double stranded RNA sensing pathways such as RIG-I and MDA5. RNA interference studies excluded the activation of the Toll-like receptor and NF-KappaB pathways in the action of ribavirin. In conclusion, our study suggests that ribavirin, acting via a novel innate mechanism, potentiates the anti-HCV effect of interferon. Understanding the mechanism of action of ribavirin would be valuable in identifying novel antivirals.

2012-01-01 | GSE23031 | GEO

Ribavirin Treated Huh7.5.1 Cells

2012-01-01 | E-GEOD-23031 | biostudies-arrayexpress

Growth inhibition and transcriptional effects of ribavirin in lymphoma

Project description:The cutaneous T-cell lymphoma Hut78 was treated with ribavirin for 120 h, and the gene expression of the treated cells was compared with respect to the expression of the cells without treatment. We evaluated the effect of treatment with ribavirin upon gene expression in a cutaneous T-cell lymphoma model, Hut78. Ribavirin treatment decreased approximately 90% of the viability of Hut78 cells. A complete genomic analysis of transcriptomic status after treatment with ribavirin of cutaneous T cell lymphoma Hut78 revealed an impact on the overall expression of transcripts.

2020-08-02 | GSE118066 | GEO

Effect of Ribavirin on Viral Kinetics and Liver Gene Expression in Chronic Hepatitis C

Project description:Background/Aims: Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C. Methods: 70 treatment-naïve patients were randomized to 4 weeks of ribavirin (1000-1200 mg/d) or none, followed by PEG-IFN alfa-2a and ribavirin at standard doses and durations. Patients were randomized to undergo a liver biopsy either 24 hours before, or 6 hours after starting PEG-IFN. Hepatic gene expression was assessed by microarray and interferon-stimulated gene (ISG) expression quantified by the nCounter platform. Temporal changes in ISG expression were assessed by qPCR in peripheral-blood mononuclear cells (PBMC) and by serum levels of IP-10. Results: After four weeks of ribavirin monotherapy, HCV levels decreased by 0.5±0.5 log10 (p=0.009 vs. controls) and ALT by 33% (p<0.001). Ribavirin pretreatment, while modestly augmenting the induction of ISGs by PEG-IFN, did not modify the virological response to subsequent PEG-IFN and ribavirin treatment. However, biochemical, but not virological response to ribavirin monotherapy predicted response to subsequent combination treatment (rapid virological response, 71% in biochemical responders vs. 22% non-responders, p=0.01; early virological response, 100% vs. 68%, p=0.03, sustained virological response 83% vs. 41%, p=0.053). Ribavirin monotherapy lowered serum IP-10 levels but had no effect on ISG expression in PBMC. Conclusion: Ribavirin is a weak antiviral but its clinical effect in combination with PEG-IFN seems to be mediated by a separate, indirect mechanism, which may act to reset the interferon responsiveness in HCV-infected liver. Ribavirin pretreatment does not alter the clinical outcome of subsequent combination therapy.

2013-03-08 | GSE38663 | GEO